Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001);The current and future role of screening in the era of HPV vaccination

Gynecologic Oncology

Volumn 109, Issue 2 SUPPL., 2008, Pages 270-

  Myers, Evan ^a   Huh, Warner K ^b   Wright, Jason D ^c   Smith, Jennifer S ^d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA HOSPITAL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d IL   (United States)

Author keywords

Cervical cancer; HPV; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INVASION; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DISEASE ASSOCIATION; HUMAN; INCIDENCE; MORTALITY; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; VIRUS INFECTION; WART VIRUS;

EID: 43349090027     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.05.022     Document Type: Erratum

References (75)

1. D.M. Parkin F. Bray J. Ferlay P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 Mar-Apr 2005 74 108
2. A. Jemal Cancer Statistics 2007 CA Cancer J Clin 57 2007 43 66 2007
3. C.D. Runowicz Molecular screening for cervical cancer—time to give up Pap tests? New Engl J Med 357 16 Oct 18 2007 1650 1653
4. M.F. Janicek H.E. Averette Cervical cancer: prevention, diagnosis, and therapeutics CA Cancer J Clin 51 2 Mar-Apr 2001 92 114 quiz 5–8
5. ACS Cancer facts & figures 2007 2007 American Cancer Society
6. Berg A, Atkins D. Screening for cervical cancer. Recommendations and rationale. Guide to Clinical Preventive Services. 2nd Ed. US Preventive Services Task Force. Rockville, MD: Agency to Health Care Research and Quality. 2004.
7. H.C. Kitchener P.E. Castle J.T. Cox Chapter 7: achievements and limitations of cervical cytology screening Vaccine 24 Suppl 3 Aug 21 2006 S63 S70
8. CRUK. Cancer Research UK Cervical cancer 2007 Available at: http://info.cancerresearchuk.org/cancerstats/types/cervix/mortality/ . Accessed October 15, 2007.
9. IARC. International Agency for Research on Cancer. IARC Screening Group Cervical cancer 2005 Available at http://screening.iarc.fr/cervicalindex.php
10. National Cancer Institute The Pap test: questions and answers 2007 Available at: http://www.cancer.gov/cancertopics/factsheet/Detection/Pap-test . Accessed January 23, 2008.
11. S. Feldman How often should we screen for cervical cancer? New Engl J Med 349 16 Oct 16 2003 1495 1496
12. American Cancer SocietyDetailed Guide: Cervical Cancer How is cervical cancer staged? 2006 Available at: www.cancer.org . Accessed February 4, 2008.
13. T.C. Wright Jr. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol 50 2 Jun 2007 313 323
14. K. Nanda D.C. McCrory E.R. Myers L.A. Bastian V. Hasselblad J.D. Hickey Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review Ann Intern Med 132 10 May 16 2000 810 819
15. E.L. Franco E. Duarte-Franco A. Ferenczy Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection CMAJ 164 7 Apr 3 2001 1017 1025
16. D.E. Cohn T.J. Herzog New innovations in cervical cancer screening Clin Obstet Gynecol 44 3 Sep 2001 538 549
17. J. Linder Recent advances in thin-layer cytology Diagn Cytopatho 18 1 Jan 1998 24 32
18. J. Linder D. Zahniser ThinPrep Papanicolaou testing to reduce false-negative cervical cytology Arch Pathol Lab Med 122 2 Feb 1998 139 144
19. R.G.L. Sankaranarayanan M. Jacob J. Sellors S. Robles A critical assessment of screening methods for cervical neoplasia Int J Gynecol Obstet 89 2005 S4 S12
20. G. Ronco J. Cuzick P. Pierotti M.P. Cariaggi P. Dalla Palma C. Naldoni Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial BMJ 335 7609 Jul 7 2007 28
21. C. Celik K. Gezginc H. Toy S. Findik O. Yilmaz A comparison of liquid-based cytology with conventional cytology Int J Gynaecol Obstet 100 2 Feb 2008 163 166
22. J. Obwegeser S. Brack Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep test with the conventional Pap test, including follow-up of HSIL cases Acta Cytol 45 5 2001 709 714
23. E. Davey A. Barratt L. Irwig S.F. Chan P. Macaskill P. Mannes Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review Lancet 367 9505 Jan 14 2006 122 132
24. M. Arbyn C. Bergeron P. Klinkhamer P. Martin-Hirsch A.G. Siebers J. Bulten Liquid compared with conventional cervical cytology: a systematic review and meta-analysis Obstet Gynecol 111 1 Jan 2008 167 177
25. B. Strander A. Andersson-Ellstrom I. Milsom T. Radberg W. Ryd Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program: a prospective randomized study Cancer 111 5 Oct 25 2007 285 291
26. H. Noorani A. Brown B.S. Skidmore Liquid-based cytology and human papillomavirus testing in cervical cancer screening. Canadian Coordinating Office for Health Technology Assessment 2003 Technology Report #40
27. G. Sawaya Evidence-based medicine versus liquid-based cytology Obstet Gynecol 111 2008 2 3
28. E. Dunne Prevelence of HPV infection among females in the United States JAMA 297 8 2007 813 819
29. J.M. Walboomers M.V. Jacobs M.M. Manos F.X. Bosch J.A. Kummer K.V. Shah Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 1 Sep 1999 12 19
30. CDC. Centers for Disease Control and Prevention Genital HPV infection—CDC fact sheet. Centers for Disease Control and Prevention 2004 Available at: http://www.cdc.gov/std/HPV/STDFact-HPV.htm
31. F.X. Bosch A. Lorincz N. Munoz C.J. Meijer K.V. Shah The causal relation between human papillomavirus and cervical cancer J Clin Pathol 55 4 Apr 2002 244 265
32. F. Bosch Human papillomavirus and cervical cancer burden and assessment of causality J Natl Cancer Inst Monogr 31 2003 3 13
33. N. Munoz F.X. Bosch X. Castellsague M. Diaz S. de Sanjose D. Hammouda Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int J Cancer 111 2 Aug 20 2004 278 285
34. G. Koliopoulos M. Arbyn P. Martin-Hirsch M. Kyrgiou W. Prendiville E. Paraskevaidis Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies Gynecol Oncol 104 1 Jan 2007 232 246
35. P.E. Castle C.M. Wheeler D. Solomon M. Schiffman C.L. Peyton Interlaboratory reliability of Hybrid Capture 2 Am J Clin Pathol 122 2 Aug 2004 238 245
36. P.E. Castle A.T. Lorincz I. Mielzynska-Lohnas D.R. Scott A.G. Glass M.E. Sherman Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible J Clin Microbiol 40 3 Mar 2002 1088 1090
37. M.H. Stoler M. Schiffman Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study JAMA 285 11 Mar 21 2001 1500 1505
38. M. Confortini A. Bondi M.P. Cariaggi F. Carozzi P. Dalla Palma B. Ghiringhello Interlaboratory reproducibility of liquid-based equivocal cervical cytology within a randomized controlled trial framework Diagn Cytopathol 35 9 Sep 2007 541 544
39. M.E. Sherman A. Dasgupta M. Schiffman R. Nayar D. Solomon The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda 2001 System for classifying cervical cytology Cancer 111 1 Feb 25 2007 15 25
40. C.M. Wheeler W.C. Hunt M. Schiffman P.E. Castle Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer J Infect Dis 194 9 Nov 1 2006 1291 1299
41. P. Naucler W. Ryd S. Tornberg A. Strand G. Wadell K. Elfgren Human papillomavirus and Papanicolaou tests to screen for cervical cancer New Engl J Med 357 16 Oct 18 2007 1589 1597
42. M. Mayrand E. Duarte-Franco I. Rodrigues S. Walter J. Hanley A. Ferenczy Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer NEJM 357 16 2007 1579 1588
43. P. Klinkamer W. Meerding P. Rosier A. Hanselaar Liquid-based cervical cytology Cancer 99 2003 263 271
44. S.J. Goldie L. Gaffikin J.D. Goldhaber-Fiebert A. Gordillo-Tobar C. Levin C. Mahe Cost-effectiveness of cervical-cancer screening in five developing countries New Engl J Med 353 20 Nov 17 2005 2158 2168
45. S.J. Goldie J.J. Kim E. Myers Chapter 19: cost-effectiveness of cervical cancer screening Vaccine 24 Suppl 3 Aug 21 2006 S164 S170
46. S. McMeekin K. McGonigle S. Vasilev Cervical cancer prevention: toward cost-effective screening MedGenMed 1 2 1999 1 14
47. S.J. Goldie Chapter 15: public health policy and cost-effectiveness analysis J Natl Cancer Inst Monogr 31 2003 102 110
48. H.W. Chesson J.M. Blandford T.L. Gift G. Tao K.L. Irwin The estimated direct medical cost of sexually transmitted diseases among American youth, 2000 Perspect Sex Reprod Health 36 1 Jan-Feb 2004 11 19
49. M.C. Weinstein A QALY is a QALY—or is it? J Health Econ 7 3 Sep 1988 289 290
50. M.C. Weinstein Theoretically correct cost-effectiveness analysis Med Decis Making 19 4 Oct-Dec 1999 381 382 discussion 3–4
51. S. Goldie A public health approach to cervical cancer control: considerations of screening and vaccination strategies Int J Gynaecol Obstet 94 Suppl 1 Nov 2006 S95 S105
52. E.R. Myers D.C. McCrory S. Subramanian N. McCall K. Nanda S. Datta Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening Obstet Gynecol 96 5 Pt 1 Nov 2000 645 652
53. M. Kyrgiou G. Koliopoulos P. Martin-Hirsch M. Arbyn W. Prendiville E. Paraskevaidis Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis Lancet 367 9509 Feb 11 2006 489 498
54. G.F. Sawaya K.J. McConnell S.L. Kulasingam H.W. Lawson K. Kerlikowske J. Melnikow Risk of cervical cancer associated with extending the interval between cervical-cancer screenings New Engl J Med 349 16 Oct 16 2003 1501 1509
55. J. Nuovo J. Melnikow L.P. Howell New tests for cervical cancer screening Am Fam Physician 64 5 Sep 1 2001 780 786
56. D. Saslow P.E. Castle J.T. Cox D.D. Davey M.H. Einstein D.G. Ferris American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors CA Cancer J Clin 57 1 Jan–Feb 2007 7 28
57. CDC. Centers for Disease Control. US Department of Health and Human Services Healthy People 2010. 3-Cancer 2007 Available at: http://www.healthypeople.gov/document/html/volume1/03cancer.htm . Accessed October 16, 2007.
58. J.S. Smith L. Lindsay B. Hoots J. Keys S. Franceschi R. Winer Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update International journal of cancer 121 3 Aug 1 2007 621 632
59. J. Paavonen D. Jenkins F.X. Bosch P. Naud J. Salmeron C.M. Wheeler Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 9580 Jun 30 2007 2161 2170
60. E.L. Franco J. Cuzick A. Hildesheim S. de Sanjose Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination Vaccine 24 Suppl 3 Aug 21 2006 S171 S177
61. A.T. Newall P. Beutels J.G. Wood W.J. Edmunds C.R. MacIntyre Cost-effectiveness analyses of human papillomavirus vaccination Lancet Infect Dis 7 4 Apr 2007 289 296
62. M. Gold J. Siegel L. Russell M. Weinstein Cost-effectiveness in health and medicine 1996 NY Oxford University Press New York
63. S.L. Kulasingam E.R. Myers Potential health and economic impact of adding a human papillomavirus vaccine to screening programs JAMA 290 6 Aug 13 2003 781 789
64. S.J. Goldie M. Kohli D. Grima M.C. Weinstein T.C. Wright F.X. Bosch Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine J Natl Cancer Inst 96 8 Apr 21 2004 604 615
65. S.L. Kulasingam S. Pagliusi E. Myers Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S Vaccine 25 48 Nov 23 2007 8110 8113
66. G.F. Sawaya K. Smith-McCune HPV vaccination—more answers, more questions New Engl J Med 356 19 May 10 2007 1991 1993
67. L.A. Koutsky D.M. Harper Chapter 13: current findings from prophylactic HPV vaccine trials Vaccine 24 Suppl 3 Aug 21 2006 S114 S121
68. Brown D. For the Future Study Group. HPV type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia, and adenocarcinoma in situ caused by oncogenic HPV types in addition to 16/18. Presentation: G-1720b. Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Il 2007.
69. S.L. Block T. Nolan C. Sattler E. Barr K.E. Giacoletti C.D. Marchant Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women Pediatrics 118 5 Nov 2006 2135 2145
70. K.S. Reisinger S.L. Block E. Lazcano-Ponce R. Samakoses M.T. Esser J. Erick Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial Pediatr Infect Dis J 26 3 Mar 2007 201 209
71. E.H. Elbasha E.J. Dasbach R.P. Insinga Model for assessing human papillomavirus vaccination strategies Emerg Infect Dis 13 1 Jan 2007 28 41
72. CDC. CDC ACIP recommendations for the use of quadrivalent HPV vaccine. Morbidity and mortality weekly report 2006
73. R.P. Insinga A.G. Glass B.B. Rush The health care costs of cervical human papillomavirus-related disease Am J Obstet Gynecol 191 1 Jul 2004 114 120
74. G.D. Sanders A.V. Taira Cost-effectiveness of a potential vaccine for human papillomavirus Emerg Infect Dis 9 1 Jan 2003 37 48
75. A.V. Taira C.P. Neukermans G.D. Sanders Evaluating human papillomavirus vaccination programs Emerg Infect Dis 10 11 Nov 2004 1915 1923